Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of QLC1101 in Healthy Subjects
NCT06980909Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of QLC1101 in solid tumor (3 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 144 hours, Area Under the Curve at 144 hours and 4 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
QLC1101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06980909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980909.